683 Capital Management’s Indaptus Therapeutics INDP Stock Holding History

683 Capital Management’s Portfolio INDP Stock Details INDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-67	Closed	-$1.1M	–	181
2019 Q1	$1.1M	Hold	67	–	–	0.1%	92
2018 Q4	$1.13M	Hold	67	–	–	0.07%	105
2018 Q3	$848K	Hold	67	–	–	0.06%	101
2018 Q2	$660K	Buy	+67	New	+$743K	0.04%	107

Other funds holding INDP

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

683 Capital Management's INDP Position: Q2 2019 in Review

683 Capital Management sold out of Indaptus Therapeutics (INDP) in Q2 2019, closing a stake of 67 shares — an estimated $1.1M sold.

683 Capital Management first reported a position in INDP in Q2 2018 and held it in 4 quarters. The position peaked at $1.13M in Q4 2018. 47 funds tracked by Wall St. Rank hold INDP as of Q2 2019.

683 Capital Management reported no remaining Indaptus Therapeutics position as of Q2 2019 after selling out during the quarter.
683 Capital Management sold 67 Indaptus Therapeutics shares in Q2 2019, an estimated $1.1M.
683 Capital Management first reported a position in Indaptus Therapeutics in Q2 2018 and held it in 4 quarters.
683 Capital Management's Indaptus Therapeutics position peaked at $1.13M in Q4 2018.
47 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q2 2019.

Based on 683 Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.